PubMed=27231123; DOI=10.1158/2159-8290.CD-15-1442; PMCID=PMC5458737
Saha S.K., Gordan J.D., Kleinstiver B.P., Vu P., Najem M.S., Yeo J.-C., Shi L., Kato Y., Levin R.S., Webber J.T., Damon L.J., Egan R.K., Greninger P., McDermott U., Garnett M.J., Jenkins R.L., Rieger-Christ K.M., Sullivan T.B., Hezel A.F., Liss A.S., Mizukami Y., Goyal L., Ferrone C.R., Zhu A.X.-X., Joung J.K., Shokat K.M., Benes C.H., Bardeesy N.M.
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.
Cancer Discov. 6:727-739(2016)

PubMed=35640676; DOI=10.1016/j.ajpath.2022.05.007; PMCID=PMC9472155
Isidan A., Yenigun A., Soma D., Aksu E., Lopez K., Park Y., Cross-Najafi A., Li P., Kundu D., House M.G., Chakraborty S., Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.
Development and characterization of human primary cholangiocarcinoma cell lines.
Am. J. Pathol. 192:1200-1217(2022)

PubMed=39026794; DOI=10.1101/2024.07.04.601970; PMCID=PMC11257448
Vijay V., Karisani N., Shi L., Hung Y.-H., Vu P., Kattel P., Kenney L., Merritt J., Adil R., Wu Q.-B., Zhen Y.-L., Morris R., Kreuzer J., Kathiresan M., Herrera Lopez X.I., Ellis H., Gritti I.G., Lecorgne L., Farag I., Popa A., Shen W., Kato H., Xu Q., Balasooriya E.R., Wu M.-J., Chaturantabut S., Kelley R.K., Cleary J.M., Lawrence M.S., Root D.E., Benes C.H., Deshpande V., Juric D., Sellers W.R., Ferrone C.R., Haas W., Vazquez F., Getz G., Bardeesy N.M.
Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.
bioRxiv 2024:07.04.601970-07.04.601970(2024)